There are currently 2876 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT06064877
Recruiting
The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is that ficlatuzumab combined with cetuximab is superior to cetuximab alone in terms of progression-free survival and/or overall survival.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: MD Anderson Cancer Center, Houston, Texas +1 locations
Conditions: Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Register for Updates
A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
NCT06540066
Recruiting
This is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of BGB-B3227, a humanized immunoglobulin G1 (IgG1) antibody. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-B3227 as a monotherapy or in combination with tislelizumab with or without chemotherapy in participants with selected advanced or metastatic solid tumors. The study will also identify recommended d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Md Anderson Cancer Center, Houston, Texas
Conditions: Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer, Metastatic Solid Tumor
Register for Updates
Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial
NCT06593431
Recruiting
The EXPAND trial (EXtending outcomes for PAncreas cancer patients with Nominal oligometastatic Disease) is a randomized phase III trial assessing the efficacy of MDT to improve PFS and OS for patients with oligometastatic pancreatic ductal adenocarcinoma (PDAC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Pancreas Cancer, Oligometastatic
Register for Updates
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
NCT05238883
Recruiting
The purpose of this study is to test the safety and tolerability of HFB200301 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study. During the escalation part, groups of participants will receive increasing doses of HFB200301 as a monotherapy or in combination with tislelizumab until a safe and tolerable dose of HFB200301 as a single agent or combination therapy is determined. During the expansion part, participants will take... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: The University of Texas, MD Anderson Cancer Center, Houston, Texas
Conditions: Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma, Testicular Germ Cell Tumor, Cervical Cancer, Mesothelioma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Register for Updates
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
NCT05308264
Recruiting
Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Low Risk Myelodysplastic Syndromes
Register for Updates
Neuromodulation of the Fear Extinction Circuit Using Temporally and Anatomically Specific TMS in Humans
NCT05368987
Recruiting
This study aims to explore the mechanisms of how transcranial magnetic stimulation (TMS) impacts fear circuits. The overarching objectives are to understand how varying TMS parameters affect targeted brain regions in order to optimize its impact on enhancing fear extinction memory consolidation in a population with known fear extinction deficiencies: post-traumatic stress disorder (PTSD). 250 subjects will take part in this research study across UTHealth Houston. The study will include prelimina... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/09/2025
Locations: UTHealth Houston, Houston, Texas
Conditions: PTSD
Register for Updates
FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study
NCT05639543
Recruiting
The purpose of this trial is to assess dose related safety, efficacy, and pharmacokinetics (PK) of INT-787 in participants with severe alcohol-associated hepatitis (sAH).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/09/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Alcohol Associated Hepatitis
Register for Updates
Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
NCT06014502
Recruiting
The purpose of this Phase 1a/1b clinical trial is to test the safety of an investigational drug called IMGS-001 and to determine how well it can work in treating patients with advanced solid tumors that have come back or are not improving after receiving other drugs that are commonly used for their cancer. Phase 1a (Part 1) will test the safety of five different doses of IMGS-001 to use in further studies. Patients with cancer that have advanced or spread to other parts of the body following tre... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumor
Register for Updates
Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1
NCT06083883
Recruiting
The goal of this clinical research study is to find a recommended dose of donated NK cells that can be given along with chemotherapy to patients with advanced cancers. The safety and effects of this therapy will also be studied.
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
04/09/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Synovial Sarcoma, Myxoid/Round Cell Liposarcoma
Register for Updates
Use Electroencephalogram to Study Neural Dynamics of Fear Conditioning and Avoidance Learning Circuit in Humans
NCT06240052
Recruiting
The purpose of this study is to examine which event-related potentials (ERPs) and event-related oscillations (EROs) are associated with fear conditioning, avoidance learning, and memory recall for fear and avoidance, where are the source generators of the observed scalp EEG activity, the impact of fear and avoidance learning on the decision to avoid or not to avoid conditioned stimuli , to examine the large-scale functional connectivity across distributed brain regions across experimental phases... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/09/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Neural Dynamics of the Acquisition and Retention of Fear Learning and Active Avoidance Learning
Register for Updates
A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions
NCT06308419
Recruiting
To find a recommended dose of gemcitabine and nab-sirolimus that can be given in combination to participants with advanced leiomyosarcomas or soft-tissue sarcomas.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Leiomyosarcoma, Soft-tissue Sarcomas
Register for Updates
A Study of VET3-TGI in Patients With Solid Tumors
NCT06444815
Recruiting
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with pembrolizumab in patients with solid tumors (STEALTH-001).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Kidney Cancer, Renal Cell Carcinoma, Melanoma Stage IV, Merkel Cell Carcinoma of Skin, Mesothelioma, Non-small Cell Lung Cancer
Register for Updates